Loading clinical trials...
Loading clinical trials...
Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection (Zopocianine), a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent, for the Intraoperative Imaging of Prostate Cancer
Conditions
Interventions
0.03mg/kg ZOPOCIANINE given day of surgery
0.06mg/kg ZOPOCIANINE given day of surgery
+2 more
Locations
3
United States
Indiana University Health North Hospital
Carmel, Indiana, United States
Indiana University Health Methodist Hospital
Indianapolis, Indiana, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Start Date
April 2, 2025
Primary Completion Date
May 1, 2026
Completion Date
June 1, 2026
Last Updated
February 27, 2026
NCT07004582
NCT07115914
NCT06822452
NCT06992232
NCT06840535
NCT06670924
Lead Sponsor
Clinton Bahler
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions